HK1130053A1 - 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions - Google Patents

4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Info

Publication number
HK1130053A1
HK1130053A1 HK09108045.9A HK09108045A HK1130053A1 HK 1130053 A1 HK1130053 A1 HK 1130053A1 HK 09108045 A HK09108045 A HK 09108045A HK 1130053 A1 HK1130053 A1 HK 1130053A1
Authority
HK
Hong Kong
Prior art keywords
fluorophenoxy
phenylmethyl
synthesis
pharmaceutical compositions
piperidine
Prior art date
Application number
HK09108045.9A
Other languages
English (en)
Inventor
Venero Aurelio Orjales
Pestana Ramon Mosquera
Duran Ma Carmen Pumar
Avello Antonio Toledo
Mori Gonzalo Canal
Martin Maravillas Bordell
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of HK1130053A1 publication Critical patent/HK1130053A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK09108045.9A 2006-05-12 2009-09-03 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions HK1130053A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380112A EP1854785A1 (en) 2006-05-12 2006-05-12 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
US11/486,350 US20070265306A1 (en) 2006-05-12 2006-07-13 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
PCT/EP2007/053582 WO2007131846A1 (en) 2006-05-12 2007-04-12 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1130053A1 true HK1130053A1 (en) 2009-12-18

Family

ID=37061190

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108045.9A HK1130053A1 (en) 2006-05-12 2009-09-03 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Country Status (24)

Country Link
US (2) US20070265306A1 (sl)
EP (2) EP1854785A1 (sl)
JP (1) JP2009536962A (sl)
KR (1) KR20090009971A (sl)
CN (1) CN101443312B (sl)
AT (1) ATE501121T1 (sl)
AU (1) AU2007251663B2 (sl)
BR (1) BRPI0710856A2 (sl)
CA (1) CA2651933A1 (sl)
CY (1) CY1111460T1 (sl)
DE (1) DE602007013040D1 (sl)
DK (1) DK2032534T3 (sl)
ES (1) ES2362683T3 (sl)
HK (1) HK1130053A1 (sl)
HR (1) HRP20110333T1 (sl)
MX (1) MX2008014439A (sl)
MY (1) MY148406A (sl)
NO (1) NO20085052L (sl)
NZ (1) NZ572714A (sl)
PL (1) PL2032534T3 (sl)
RS (1) RS51858B (sl)
RU (1) RU2412169C2 (sl)
SI (1) SI2032534T1 (sl)
WO (1) WO2007131846A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854785A1 (en) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
US7888386B2 (en) * 2008-07-24 2011-02-15 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
RU2535669C2 (ru) * 2009-07-13 2014-12-20 Тереванс, Инк. 3-феноксиметилпирролидиновые соединения
JP5714580B2 (ja) * 2009-07-21 2015-05-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−フェノキシメチルピロリジン化合物
EP2627630B1 (en) 2010-10-11 2014-12-31 Theravance Biopharma R&D IP, LLC Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
US9002322B2 (en) * 2011-09-29 2015-04-07 Apple Inc. Authentication with secondary approver
CN104887675B (zh) * 2014-03-05 2018-08-07 江苏恩华药业股份有限公司 [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
MXPA06012505A (es) * 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
EP1854785A1 (en) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Also Published As

Publication number Publication date
AU2007251663A1 (en) 2007-11-22
HRP20110333T1 (hr) 2011-06-30
ATE501121T1 (de) 2011-03-15
RU2412169C2 (ru) 2011-02-20
CN101443312A (zh) 2009-05-27
DE602007013040D1 (de) 2011-04-21
MY148406A (en) 2013-04-30
MX2008014439A (es) 2009-01-21
US20070265306A1 (en) 2007-11-15
EP2032534B1 (en) 2011-03-09
BRPI0710856A2 (pt) 2011-05-17
NO20085052L (no) 2008-12-04
EP1854785A1 (en) 2007-11-14
AU2007251663B2 (en) 2012-04-05
RS51858B (en) 2012-02-29
ES2362683T3 (es) 2011-07-11
US20100004283A1 (en) 2010-01-07
EP2032534A1 (en) 2009-03-11
CN101443312B (zh) 2011-07-06
WO2007131846A1 (en) 2007-11-22
RU2008148941A (ru) 2010-06-20
PL2032534T3 (pl) 2011-08-31
DK2032534T3 (da) 2011-04-26
CA2651933A1 (en) 2007-11-22
NZ572714A (en) 2010-08-27
JP2009536962A (ja) 2009-10-22
SI2032534T1 (sl) 2011-06-30
CY1111460T1 (el) 2015-08-05
KR20090009971A (ko) 2009-01-23

Similar Documents

Publication Publication Date Title
HK1130053A1 (en) 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
MX2010006179A (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
NO20090328L (no) Nye forbindelser 385
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2009155121A3 (en) Inhibitors of pi3 kinase
IN2012DN02968A (sl)
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
MY160357A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
PL2150530T3 (pl) Podstawione pochodne sulfonamidu
NO20091185L (no) Piperidinderivater
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
ZA200806778B (en) N-Hydroxyacrylamide compounds
MX2007010400A (es) Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
NZ598505A (en) 1,2-dihydro-2-oxoquinoline compounds as 5-ht4 receptor ligands
WO2008087654A3 (en) PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
WO2008145524A3 (en) 4,4-disubstituted piperidine derivatives
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
TW200728281A (en) Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150412